Scandinavian Biolabs

Scandinavian Biolabs is a Copenhagen-based haircare company that develops drug-free products aimed at early-stage hair thinning. Founded in 2020, it positions its formulas as a non-prescription alternative to hair-loss drugs such as finasteride and minoxidil, built around a proprietary active blend the company calls Bio-Pilixin. Its own press release and the trade publication Beauty Independent both date the founding to 2020 [7], while one business-database listing records 2019 [9].

The company sells chiefly online across several country-specific storefronts and, according to trade coverage, through around 50 European pharmacies and retailers. It reported a Series A funding round in September 2024 and describes an aim of becoming, in the words of chief executive Anders Reckendorff, "the No. 1 functional haircare company" [7].

Scandinavian Biolabs was established in Copenhagen by three co-founders: Anders Reckendorff, who serves as chief executive; Niels Konradi, chief operating officer; and Christian Harboe, chief growth officer [7]. The company began as a direct-to-consumer brand, selling online before expanding into pharmacy and retail channels.

The founding premise was to treat the early stages of hair loss without prescription medication. The company frames its products as "science-backed, non-invasive, preventative" and targeted at people noticing thinning before it becomes advanced. That drug-free stance — avoiding the active pharmaceutical ingredients used in conventional hair-loss treatments — is the central point of difference the brand draws on across its marketing.

The company's stated tagline is "Driving stem cell science for hair care that respects your health," and its positioning centres on offering an evidence-led routine without the side effects associated with prescription drugs. Its serums are described as drug-free, containing neither finasteride nor minoxidil, and as suitable for daily at-home use.

Scandinavian Biolabs directs its products at two broad groups. According to Beauty Independent, its customer base skews roughly 60% male, concentrated in the 25-to-40 age range, with the largest shares in the United Kingdom and Germany; the brand also markets women's formulas aimed at postpartum and menopausal thinning [7]. The company reports that most new direct customers take up a subscription rather than a one-off purchase.

The brand's flagship is the Bio-Pilixin Activation Serum, sold in separate men's and women's versions, alongside a Hairline Booster and a bundled Hair Growth Routine. Pricing is set on a monthly subscription basis, and the serum is offered with a 150-day money-back guarantee.

Bio-Pilixin is presented as working in three ways: supporting scalp blood flow, helping to rebalance the hair-growth cycle, and delivering active compounds to the follicle. The company attributes the warming, tingling sensation of the serum to a proprietary agent it markets as HotFlux (the ingredient vanillyl butyl ether), and it uses a turmeric-derived stem-cell extract it brands Capilia Longa. On its science page, the company states that this extract yields "exosomes" — microscopic delivery particles it describes as "up to 462x smaller than pores" — that reach follicle cells directly [3].

Scandinavian Biolabs supports these products with clinical figures drawn from a company-cited study of 30 participants over 150 days. According to the brand, "93% had measurably less hair loss after 150 days" and "73% had a clinically tested increase in hair density" [3]. The company also states that its serum was dermatologist-tested on 25 volunteers with no reported irritation. These results are the brand's own and have not been independently verified.

In September 2024, Scandinavian Biolabs raised a Series A round of €4 million (reported as roughly $4.5 million) led by the Paris-based Auréa Group, with SevenVentures and Blazar Capital participating; the company had earlier taken $1.3 million in pre-seed funding from Blazar Capital [7]. Trade coverage placed the company's headcount at about 25 people, most based in Copenhagen, and reported that it was on track for revenue in the low tens of millions of euros for 2024.

The brand set up a United States warehouse in 2023 to support North American expansion, and it has continued to widen its geographic reach across the United Kingdom, Germany, the Nordics and the US. Its sales are predominantly direct-to-consumer, with a smaller share through Amazon and retail, and the company lists pharmacy and retail partners including John Bell & Croyden, Flaconi and Helsam.

Scandinavian Biolabs has been covered in beauty and general-interest press. Beauty Independent profiled the brand's positioning, clinical claims and 2024 funding round, and the company's own media page lists features in outlets including Cosmopolitan and Men's Health during 2024. The startup publication EU-Startups reported the €4 million raise in September 2024 [8].

The company states that it partners with CleanHub, an organisation focused on preventing plastic waste from reaching the oceans, as part of its stated environmental commitments. No third-party sustainability certifications were identified in the sources reviewed.

Scandinavian Biolabs is an actively trading company. It operates country-specific storefronts, secured Series A funding in 2024, and its site remained live with current pricing at the time of review. The company cites a customer base that has grown over time — from about 140,000 supported customers stated in its September 2024 press release to 191,619 cited on its site in a 2026 check [2][5].